Johnston W W, Szpak C A, Thor A, Schlom J
Cancer Res. 1986 Dec;46(12 Pt 1):6462-70.
Monoclonal antibody B72.3, reactive with a high-molecular-weight glycoprotein tumor-associated antigen (designated TAG-72), has been previously shown to be reactive with formalin-fixed paraffin-embedded tissue sections of adenocarcinomas of the ovary, colon, and breast and not a variety of normal adult tissues. It has demonstrated utility as an immunocytochemical adjunct to diagnose carcinoma in cell block and cytocentrifuge preparations of human serous effusions, with selective reactivity for tumor cells (particularly adenocarcinoma) over reactive mesothelium. In this study, fine needle aspiration biopsies of 127 lung cancers (93 primary and 34 metastatic tumors) as well as 18 benign lung lesions were analyzed with monoclonal antibody B72.3 using avidin-biotin-peroxidase techniques. Monoclonal antibody B72.3 showed reactivity with 100% of the 27 lung adenocarcinomas and adenosquamous carcinomas, with greater than or equal to 10% of tumor cells showing reactivity in 22 of 27. A lesser percentage of squamous cell carcinomas (24 of 31) and large cell carcinomas (7 of 13) were immunoreactive, and of these several were weakly reactive with less than or equal to 1% tumor cells reacting. In contrast, monoclonal antibody B72.3 failed to react with any of the 21 small cell carcinomas or one carcinoid tumor evaluated. In 35 patients tumor-bearing tissue was resected, and formalin-fixed tissue sections were also evaluated. The staining pattern and percentage of tumor cells positive in the aspiration biopsies were, in most cases, highly predictive of the reactivity observed in corresponding resected tumor. Metastatic adenocarcinomas to lung from various body sites were also immunoreactive with monoclonal antibody B72.3; however, a variety of other tumor types (including 13 melanomas) failed to stain. Staining by monoclonal antibody B72.3 was not noted in any of the 18 benign lesions aspirated, with the exception of occasional fine stippling in the cytoplasm of bronchial epithelial cells. Hence, monoclonal antibody B72.3 and fine needle aspiration biopsy techniques may be of potential use in the differential diagnosis and antigenic phenotyping of a spectrum of lung neoplasms prior to surgical resection.
单克隆抗体B72.3可与一种高分子量糖蛋白肿瘤相关抗原（命名为TAG - 72）发生反应，先前已证明它可与卵巢、结肠和乳腺腺癌的福尔马林固定石蜡包埋组织切片发生反应，而与多种正常成人组织无反应。它已被证明可作为免疫细胞化学辅助手段，用于诊断人浆液性积液的细胞块和细胞离心涂片制剂中的癌，对肿瘤细胞（特别是腺癌）的反应性高于反应性间皮。在本研究中，使用抗生物素蛋白 - 生物素 - 过氧化物酶技术，用单克隆抗体B72.3对127例肺癌（93例原发性肿瘤和34例转移性肿瘤）以及18例良性肺病变的细针穿刺活检进行了分析。单克隆抗体B72.3与27例肺腺癌和腺鳞癌中的100%发生反应，其中27例中有22例肿瘤细胞反应性大于或等于10%。鳞状细胞癌（31例中的24例）和大细胞癌（13例中的7例）的免疫反应性较低，其中有几例反应较弱，肿瘤细胞反应性小于或等于1%。相比之下，单克隆抗体B72.3与评估的21例小细胞癌或1例类癌肿瘤均无反应。在35例患者中，切除了肿瘤组织，并对福尔马林固定的组织切片进行了评估。在大多数情况下，穿刺活检中肿瘤细胞的染色模式和阳性百分比高度预测了相应切除肿瘤中观察到的反应性。来自身体各个部位的肺转移性腺癌也与单克隆抗体B72.3发生免疫反应；然而，多种其他肿瘤类型（包括13例黑色素瘤）未染色。在抽取的18例良性病变中，除了支气管上皮细胞胞质中偶尔出现的细点状染色外，未观察到单克隆抗体B72.3的染色。因此，单克隆抗体B72.3和细针穿刺活检技术可能在手术切除前对一系列肺肿瘤的鉴别诊断和抗原表型分析中具有潜在用途。
